近日，博泽格霖（山东）药业有限公司的原料药产品噻托溴铵收到欧洲药品质量管理局（EDQM）颁发的原料药欧洲药典适用性证书（简称CEP证书），这也是公司获批的第三个CEP证书。

噻托溴铵是长效抗胆碱能药物，用于成人慢性阻塞性肺疾病（COPD）的维持治疗。

 

博泽格霖深耕吸入制剂用原料药领域，可供应全品系吸入原料及粉体定制化服务，始终以“国际化品质” 为核心战略；目前，公司产品已获中国、欧洲、日本等主流市场批准，为制剂客户提供更广阔的市场布局支持。 

 

未来，公司将持续精进技术与服务，坚守国际标准，稳定供应高品质原料药，与全球制剂企业携手拓展国际市场，丰富优质用药选择。

Great News! Our Tiotropium Bromide API Has Obtained the CEP Certificate!

Recently, our API Product active pharmaceutical ingredient (API)  Tiotropium Bromide Monohydrate has been granted the Certificate of Suitablility to the European Pharmacopoeia (CEP) by the European Directorate for the Quality of Medicines & HealthCare (EDQM). This is the third CEP certificate obtained by our company.

Tiotropium Bromide is a long-acting anticholinergic agent indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.

Breathgreen Pharm specializes in powder Property manipulation for pharmaceutical products , offering all respiratory therapy used API and customized powder processing services. Upholding "international quality" as our core strategy, our products have been approved in key markets including China, Europe, and Japan, supporting formulation customers in broader global market expansion.

Moving forward, we will continue to advance our technology and services, adhere to international standards, and ensure a stable supply of high-quality APIs. We look forward to partnering with global formulation companies to expand internationally and enrich the selection of high-quality medications.